A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE

Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.

  • Phase 1 Trials

    REGN3767

    REGN3767

    LAG-3 Antibody
    Cancer

    REGN5458*

    REGN5458*

    BCMA X CD3 Antibody
    Cancer

    REGN4018*

    REGN4018*

    MUC16 X CD3 Antibody
    Cancer

    REGN4659

    REGN4659

    CTLA4 Antibody
    Cancer

    REGN3048-3051

    REGN3048-3051

    Middle Eastern Respiratory Coronavirus Antibody
    MERS-CoV infection

    POZELIMAB

    POZELIMAB

    C5 Antibody
    Paroxysmal nocturnal hemoglobinuria

    REGN4461

    REGN4461

    LEPR Antibody
    Lipodystrophy and obesity

  • Phase 1 Trials

    SARILUMAB* IL-6R Antibody

    SARILUMAB*

    IL-6R Antibody
    Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

    EVINACUMAB 2

    EVINACUMAB

    ANGPTL-3 Antibody
    Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

    GARETOSMAB

    GARETOSMAB

    Activin A Antibody
    Fibrodysplasia Ossificans Progressiva (FOP)

    REGN3500

    REGN3500*

    IL-33 Antibody
    Atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD)

  • Phase 1 Trials

    ALIROCUMAB* PCSK9 Antibody

    ALIROCUMAB*

    PCSK9 Antibody
    Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

    DUPILUMAB* IL-4R Antibody

    DUPILUMAB*

    IL-4R Antibody
    Atopic dermatitis in pediatrics, asthma in pediatrics, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD)

    SARILUMAB*

    SARILUMAB*

    IL-6R Antibody
    Polymyalgia rheumatica, giant cell arteritis

Trials Footnotes

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.